Heidelberg Pharma AG

Heidelberg Pharma AG receives milestone payment from Takeda, boosting its Amanitin‑based ADC research and supporting future cancer therapy development.

Heidelberg Pharma AG has revised its financial guidance for 2025, citing recent strategic realignments and cost-saving initiatives as the reason for a downward adjustment in projected revenue and other financial metrics.

Heidelberg Pharma AG is a leading biopharmaceutical company dedicated to advancing cancer therapies and inflammatory disease treatments through innovative research and development in pharmacology and molecular biology.

Heidelberg Pharma AG, a German biopharmaceutical company, faces challenges in its financial performance and strategic decisions as it navigates the complex landscape of biotechnology and cancer therapies.